UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 431,954 Shares of Biohaven Ltd. (NYSE:BHVN)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Biohaven Ltd. (NYSE:BHVN) by 563.4% during the third quarter, Holdings Channel reports. The institutional investor owned 508,622 shares of the company’s stock after buying an additional 431,954 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Biohaven were worth $25,416,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. nVerses Capital LLC bought a new position in shares of Biohaven in the third quarter valued at $50,000. Values First Advisors Inc. bought a new position in shares of Biohaven in the third quarter valued at $78,000. Redwood Wealth Management Group LLC bought a new position in shares of Biohaven in the second quarter valued at $61,000. US Bancorp DE lifted its stake in shares of Biohaven by 57.1% in the third quarter. US Bancorp DE now owns 2,173 shares of the company’s stock valued at $109,000 after buying an additional 790 shares in the last quarter. Finally, KBC Group NV lifted its stake in shares of Biohaven by 24.5% in the third quarter. KBC Group NV now owns 2,250 shares of the company’s stock valued at $112,000 after buying an additional 443 shares in the last quarter. 88.78% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Leerink Partners raised their price target on shares of Biohaven from $55.00 to $60.00 and gave the company an “outperform” rating in a research report on Monday, September 23rd. Sanford C. Bernstein raised their price target on shares of Biohaven from $55.00 to $66.00 and gave the company an “outperform” rating in a research report on Tuesday, September 24th. William Blair raised shares of Biohaven to a “strong-buy” rating in a research report on Friday, August 30th. Robert W. Baird raised their price target on shares of Biohaven from $58.00 to $60.00 and gave the company an “outperform” rating in a research report on Monday, September 23rd. Finally, JPMorgan Chase & Co. raised their price target on shares of Biohaven from $55.00 to $68.00 and gave the company an “overweight” rating in a research report on Thursday, October 3rd. Thirteen analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $63.00.

Insider Transactions at Biohaven

In other news, Director John W. Childs acquired 21,052 shares of Biohaven stock in a transaction that occurred on Wednesday, October 2nd. The stock was bought at an average price of $47.50 per share, with a total value of $999,970.00. Following the completion of the purchase, the director now owns 21,052 shares in the company, valued at approximately $999,970. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Gregory Bailey acquired 5,000 shares of Biohaven stock in a transaction that occurred on Tuesday, September 24th. The shares were purchased at an average cost of $44.19 per share, with a total value of $220,950.00. Following the purchase, the director now owns 1,620,071 shares of the company’s stock, valued at $71,590,937.49. This represents a 0.31 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 16.00% of the company’s stock.

Biohaven Stock Up 5.4 %

BHVN opened at $46.06 on Thursday. The company has a market capitalization of $4.66 billion, a price-to-earnings ratio of -4.93 and a beta of 1.24. The firm has a 50-day moving average price of $49.65 and a 200-day moving average price of $41.55. Biohaven Ltd. has a twelve month low of $26.80 and a twelve month high of $62.21.

Biohaven (NYSE:BHVN) last posted its earnings results on Tuesday, November 12th. The company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.67) by ($0.03). On average, sell-side analysts expect that Biohaven Ltd. will post -8.85 earnings per share for the current fiscal year.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.